BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11352961)

  • 1. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.
    Kemeny N; Gonen M; Sullivan D; Schwartz L; Benedetti F; Saltz L; Stockman J; Fong Y; Jarnagin W; Bertino J; Tong W; Paty P
    J Clin Oncol; 2001 May; 19(10):2687-95. PubMed ID: 11352961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Gonen M; Stockman J; Blumgart L; Sperber D; Hummer A; Fong Y
    J Clin Oncol; 2003 Sep; 21(17):3303-9. PubMed ID: 12947066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Paty P; Gönen M; Schwartz L; Morse M; Leonard G; D'Angelica M; DeMatteo R; Blumgart L; Fong Y
    J Clin Oncol; 2005 Aug; 23(22):4888-96. PubMed ID: 16009951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma.
    Kemeny N; Eid A; Stockman J; Gonen M; Schwartz L; Tetzlaff E; Paty P
    J Surg Oncol; 2005 Aug; 91(2):97-101. PubMed ID: 16028279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
    House MG; Kemeny NE; Gönen M; Fong Y; Allen PJ; Paty PB; DeMatteo RP; Blumgart LH; Jarnagin WR; D'Angelica MI
    Ann Surg; 2011 Dec; 254(6):851-6. PubMed ID: 21975318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
    Li C; Gu Y; Zhao M; Yuan Y; Wang F; Wang Z; Li W; Luo H; Chen C; Chen G; Ding P; Wu X; Lu Z; Pan Z; Xu R; He Y; Wan D; Li Y
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1079-87. PubMed ID: 25217393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.
    Litvak DA; Wood TF; Tsioulias GJ; Chung M; Chawla SP; Foshag LJ; Morton DL; Ramming KP; Bilchik AJ
    Ann Surg Oncol; 2002 Mar; 9(2):148-55. PubMed ID: 11888871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update.
    Kemeny N; Seiter K; Conti JA; Cohen A; Bertino JR; Sigurdson ER; Botet J; Chapman D; Mazumdar M; Budd AJ
    Cancer; 1994 Feb; 73(4):1134-42. PubMed ID: 8313315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
    Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
    Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
    Kemeny N; Capanu M; D'Angelica M; Jarnagin W; Haviland D; Dematteo R; Fong Y
    Ann Oncol; 2009 Jul; 20(7):1236-41. PubMed ID: 19233901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma.
    Kemeny N; Conti JA; Cohen A; Campana P; Huang Y; Shi WJ; Botet J; Pulliam S; Bertino JR
    J Clin Oncol; 1994 Nov; 12(11):2288-95. PubMed ID: 7964942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.
    Gallagher DJ; Capanu M; Raggio G; Kemeny N
    Ann Oncol; 2007 Dec; 18(12):1995-9. PubMed ID: 17962209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
    Bilchik AJ; Wood TF; Chawla SP; Rose DM; Chung MH; Stern SS; Foshag LJ; Ramming KP
    Clin Colorectal Cancer; 2001 May; 1(1):36-42. PubMed ID: 12445377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer.
    Chen Y; Wang X; Yan Z; Wang J; Luo J; Liu Q
    Onkologie; 2012; 35(9):480-4. PubMed ID: 23007144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.
    Kemeny NE; Melendez FD; Capanu M; Paty PB; Fong Y; Schwartz LH; Jarnagin WR; Patel D; D'Angelica M
    J Clin Oncol; 2009 Jul; 27(21):3465-71. PubMed ID: 19470932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic chemotherapy with floxuridine, leucovorin and dexamethasone in continuous infusion and mitomycin-C bolus in unresectable hepatic metastases from colorectal cancer: a phase II study.
    Bertuccelli M; Falcone A; Campoccia S; Conti M; Brunetti I; Caramella D; Giulianotti PC; Mosca F; Bartolozzi C; Conte PF
    Tumori; 1999; 85(6):473-7. PubMed ID: 10774568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
    Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
    Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma.
    Lorenz M; Müller HH
    J Clin Oncol; 2000 Jan; 18(2):243-54. PubMed ID: 10637236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
    Shitara K; Munakata M; Kudo T; Kasai M; Muto O; Okada R; Mitobe S; Ishiguro A; Sakuraba H; Ikami I; Sakata Y
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2033-7. PubMed ID: 17197748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.